• CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Needham & Company LLC

    Источник: Buzz FX / 13 фев 2025 07:21:11   America/New_York


    CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Needham & Company LLC Written by MarketBeat February 13, 2025 Share Link copied to clipboard. Needham & Company LLC reaffirmed their buy rating on shares of CRISPR Therapeutics ( NAS
    Read more...
Опубликовать